Jane Allanson
Papers
2
Total Citations
70
H-Index
2
About
Jane Allanson is a pioneering analytical chemist whose work has significantly advanced the therapeutic drug monitoring of anticancer alkylating agents. Her research focuses on developing rapid, robust, and automated methods for quantifying chemotherapeutic drugs in biological matrices, directly supporting clinical pharmacology and personalized medicine. Allanson’s landmark contributions include the first validated liquid chromatography–tandem mass spectrometry (LC-MS/MS) method for the simultaneous determination of chlorambucil and its active phenyl acetic acid mustard metabolite in human serum and plasma (1999, 49 citations). This work established a new standard for speed and sensitivity in drug monitoring, enabling precise pharmacokinetic studies. She further extended this approach to melphalan (2000, 21 citations), demonstrating the versatility of automated solid-phase extraction coupled with LC-MS/MS for other nitrogen mustard agents. Her methods have been widely adopted in clinical laboratories and research settings, providing essential tools for optimizing chemotherapy dosing and reducing toxicity. Allanson’s legacy lies in bridging analytical chemistry and oncology, ensuring that patients receive safer, more effective treatment through accurate drug measurement.
Research Focus
Key Achievements
Top Papers
- 1
- 2